

# ONCOLOGY I PANEL

---

## EDITORIAL BOARD LIAISON

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP  
*Oncology Pharmacist*  
Department of Pharmacy  
Froedtert Hospital  
Milwaukee, Wisconsin

## CANCER SCREENING AND PREVENTION

### Author

Kellie L. Jones, Pharm.D., BCOP  
*Clinical Associate Professor*  
Department of Pharmacy Practice  
Purdue University  
Indianapolis, Indiana

### Reviewers

William D. Figg, Pharm.D., M.B.A. FCCP, BCPS  
*Senior Scientist and Section Head*  
Molecular and Clinical Pharmacology Section  
National Cancer Institute  
Bethesda, Maryland

Marianne McCollum, Ph.D., BSPHarm, BCPS  
*Interim Dean*  
School of Pharmacy  
Rueckert-Hartman College for Health Professions  
Regis University  
Denver, Colorado

## SUPPORTIVE CARE IN ONCOLOGY PATIENTS

### Authors

Myke R. Green, Pharm.D., BCOP  
*Oncology Pharmacy Clinical Coordinator*  
Division of Oncology/Hematology  
Arizona Cancer Center  
*Hematology/Oncology Clinical Pharmacy Specialist*  
Department of Pharmacy Services  
University Medical Center  
Tucson, Arizona

Laura R. Bobolts, Pharm.D.  
*Clinical Oncology Pharmacist*  
The Center for Women's Oncology  
Moffitt Cancer Center and Research Institute  
Tampa, Florida

### Reviewers

Margaret M. Charpentier, Pharm.D., BCPS  
*Clinical Associate Professor*  
Department of Pharmacy Practice  
College of Pharmacy  
University of Rhode Island  
Kingston, Rhode Island

Michelle M. Richardson, Pharm.D., FCCP, BCPS  
*Special and Scientific Staff*  
William B. Schwartz Division of Nephrology  
Tufts Medical Center  
*Assistant Professor of Medicine*  
Tufts University School of Medicine  
Boston, Massachusetts

## NONMALIGNANT HEMATOLOGY

### Author

Julianna A. Merten, Pharm.D., BCPS, BCOP  
*Clinical Pharmacy Specialist*  
Department of Pharmacy Services  
Mayo Clinic  
Rochester, Minnesota

### Reviewers

David M. Baribeault, B.S., BCOP  
*Clinical Advisor*  
Department of Pharmacy Optimization  
McKesson Corporation, McKesson Health Systems  
Salem, Massachusetts

Shaun P. Keegan, Pharm.D., BCPS  
*Clinical Pharmacy Specialist, Critical Care*  
Department of Pharmacy  
UC Health, University Hospital  
Cincinnati, Ohio

Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS  
*Clinical Pharmacy Specialist, Infectious Diseases*  
Pharmacy Service  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

*The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 6, Oncology I chapters:*

Nicola G. Dahl, Pharm.D.  
*Medical Writer*  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Belton, Missouri

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

---

*Consultancies:* David Baribeault (Amgen, Watson, Eisai); Shannon W. Finks (Novartis Pharmaceuticals); Myke Green (Merck, Sanofi-Aventis); Brian A. Hemstreet (Conexus Health); Viet Ho (Cephalon Oncology); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Paul Hutson (Projections Research, Inc., Mithridion); Patrick Kiel (Genzyme, Sanofi-Aventis); Michelle Richardson (Amgen, QualityMetric); Sarah Scarpace (Pfizer, TopoTarget, Millennium Pharmaceuticals, Merck); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jamie Shapiro (Genzyme); Jeffrey T. Sherer (Sturge-Weber Foundation); Judith Smith (AdvoCare);

*Stock Ownership:* Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health);

*Royalties:* William Figg (Kaplan, Springer); Lisa C. Hutchison (ASHP); Helen Leather (Genzyme, Novartis, Bayer, Amgen, Pfizer)

*Grants:* William Figg (NIH, Tracon); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants],

HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Michelle Richardson (NIH NIDDK [two grants]); Judith Smith (Merck, SignPath Pharma, Amino UP Chemical)

*Honoraria:* David Baribeault (Amgen, Eisai, Roche); Christopher Fausel (Amgen, Millennium Pharmaceuticals); Lisa C. Hutchison (ACCP, ASHP); Patrick Kiel (Genzyme); Helen LoSasso (New Jersey Society of Health-System Pharmacists, New Jersey Pharmacists Association); April Miller (Boehringer-Ingelheim, ZymoGenetics); Michelle Richardson (Amgen); Jamie Shapiro (Genzyme)

*Other:*

*Nothing to Disclose:* Ola Adejuwon, Laura Bobolts, Janet Bramell, Julianna Merten, Clarence Chant, Margaret Charpentier, Michelle Ganoff, Christy Harris, Kellie Jones, Shaun Keegan, Bernard Lee, Dayna McCauley, Marianne McCollum, April Miller, Jolynn Sessions, Sachin Shah, Audrea Szabatura, Sarah Ussery

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm).

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)